The Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye has stated that Chloroquine kills COVID-19 in its early stage.
There has been much discuss and debate on if Chloroquine should be approved as a COVID-18 treatment drug.
Prof. Mojisola Adeyeye said though Remdesivir can kill the virus at late stages, Chloroquine is a much cheaper alternative.
The NAFDAC DG noted that countries in West Africa like Ghana, Togo, and Senegal have also embraced the clinical use of Chloroquine for treatment. She said;
“In March 20, this year, just before the lockdown, I had a press briefing. At that time, people did not understand what clinical trial treatment meant. Once they hear treatment, they think you can use it anyhow. But clinical trial treatment is a research study to see whether the drug will work or not.
“In the press briefing, I said I was going through literature to see what others have done and I saw in a particular literature a reliable publication of an article about Chloroquine and Remdesivir (that time nobody was even talking of Remdesivir). This was February of this year.
“They said in the cell culture, Remdesivir and Chloroquine killed COVID-19 viruses, that is, invitro – in the laboratory. But you cannot translate that to humans unless a clinical trial is done.
“I kept looking. About two weeks or so later in early March (this was at a time when COVID-19 was at its peak in China); there was a publication where 100 patients were treated with Chloroquine across ten hospitals in six cities, including Wuhan. It said that all of them recovered from the symptoms. They called it that time pneumonia symptoms.
“In the cells, in the lab, Remdesivir and Chloroquine killed COVID-19. At what stage would they be more effective? We didn’t know at that point. Now, we are realising that Chloroquine is effective at the early stage.”